{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:30:44Z","timestamp":1771054244953,"version":"3.50.1"},"reference-count":70,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Heart failure (HF) is a worrisome cardiac pandemic with a negative prognostic impact on the overall survival of individuals. International guidelines recommend up-titration of standardized therapies in order to reduce symptoms, hospitalization rates, and cardiac death. Hyperkalemia (HK) has been identified in 3\u201318% of HF patients from randomized controlled trials and over 25% of HF patients in the \u201creal world\u201d setting. Pharmacological treatments and\/or cardio-renal syndrome, as well as chronic kidney disease may be responsible for HK in HF patients. These conditions can prevent the upgrade of pharmacological treatments, thus, negatively impacting on the overall prognosis of patients. Potassium binders may be the best option in patients with HK in order to reduce serum concentrations of K+ and to promote correct upgrades of therapies. In addition to the well-established use of sodium polystyrene sulfonate (SPS), two novel drugs have been recently introduced: sodium zirconium cyclosilicate (SZC) and patiromer. SZC and patiromer are gaining a central role for the treatment of chronic HK. SZC has been shown to reduce K+ levels within 48 h, with guaranteed maintenance of normokalemia for up to12 months. Patiromer has resulted in a statistically significant decrease in serum potassium for up to 52 weeks. Therefore, long-term results seemed to positively promote the implementation of these compounds in clinical practice due to their low rate side effects. The aim of this narrative review is to delineate the impact of new potassium binders in the treatment of patients with HF by providing a critical reappraisal for daily application of novel therapies for hyperkalemia in the HF setting.<\/jats:p>","DOI":"10.3390\/biomedicines10071721","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T21:00:28Z","timestamp":1658091628000},"page":"1721","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Optimizing Therapies in Heart Failure: The Role of Potassium Binders"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-0053","authenticated-orcid":false,"given":"Pietro","family":"Scicchitano","sequence":"first","affiliation":[{"name":"Cardiology Section, Hospital \u201cF. Perinei\u201d Altamura (BA), 70022 Altamura, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9613-5062","authenticated-orcid":false,"given":"Massimo","family":"Iacoviello","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[{"name":"Cardiology Section, Hospital \u201cF. Perinei\u201d Altamura (BA), 70022 Altamura, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micaela","family":"De Palo","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Unit, Azienda Ospedaliero-Universitaria Policlinico Bari, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Caldarola","sequence":"additional","affiliation":[{"name":"Cardiology Section, Hospital \u201cS. Paolo\u201d Bari, 70123 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Mannarini","sequence":"additional","affiliation":[{"name":"Division of University Cardiology, Cardiothoracic Department, Policlinic University Hospital, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Passantino","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Cardiac Rehabilitation, Scientific Clinical Institutes Maugeri, IRCCS Institute of Bari, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Matteo","family":"Ciccone","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2058-6865","authenticated-orcid":false,"given":"Michele","family":"Magnesa","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global Public Health Burden of Heart Failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card. Fail. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Savarese, G., Becher, P.M., Lund, L.H., Seferovic, P., Rosano, G.M.C., and Coats, A. (Cardiovasc. Res., 2022). Global Burden of Heart Failure: A Comprehensive and Updated Review of Epidemiology, Cardiovasc. Res., Epub ahead of print.","DOI":"10.1093\/cvr\/cvac013"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 355, 253\u2013259.","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e003529","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"30","author":"Raebel","year":"2012","journal-title":"Cardiovasc. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-150-9-200905050-00008","article-title":"Narrative review: Evolving concepts in potassium homeostasis and hypokalemia","volume":"150","author":"Greenlee","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1093\/eurheartj\/suy028","article-title":"Hyperkalaemia: Aetiology, epidemiology, and clinical significance","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/03007995.2018.1433141","article-title":"The prevalence of hyperkalemia in the United States","volume":"34","author":"Betts","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/03007995.2020.1775072","article-title":"Prevalence and economic burden of hyperkalemia in the United States Medicare population","volume":"36","author":"Mu","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e008912","DOI":"10.1161\/JAHA.118.008912","article-title":"Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study","volume":"7","author":"Thomsen","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality","volume":"137","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.amjcard.2016.08.078","article-title":"Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure","volume":"118","author":"Hoss","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_25","first-page":"313","article-title":"Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry","volume":"73","year":"2020","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e004675","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000505286","article-title":"Mineralcorticoid Receptor Antagonist Withdrawal for Hyperkalemia and Mortality in Patients with Heart Failure","volume":"10","author":"Lisi","year":"2020","journal-title":"Cardiorenal Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1152\/advan.00121.2016","article-title":"Physiology and pathophysiology of potassium homeostasis","volume":"40","author":"Palmer","year":"2016","journal-title":"Adv. Physiol. Educ."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Yamada, S., and Inaba, M. (2021). Potassium Metabolism and Management in Patients with CKD. Nutrients, 13.","DOI":"10.3390\/nu13061751"},{"key":"ref_31","unstructured":"(2022, May 31). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/011287s023lbl.pdf."},{"key":"ref_32","unstructured":"(2022, May 31). Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-recommends-separating-dosing-potassium-lowering-drug-sodium."},{"key":"ref_33","first-page":"296","article-title":"Effectiveness of Sodium Polystyrene Sulfonate for Short-Term Treatment of Hyperkalemia","volume":"68","author":"Batterink","year":"2015","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin. J. Am. SocNephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1060028016641427","article-title":"Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia","volume":"50","author":"Mistry","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jhm.834","article-title":"The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia","volume":"6","author":"Kessler","year":"2011","journal-title":"J. Hosp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"940320","DOI":"10.1155\/2012\/940320","article-title":"To bind or to let loose: Effectiveness of sodium polystyrene sulfonate in decreasing serum potassium","volume":"2012","author":"Sandal","year":"2012","journal-title":"Int. J. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.20987","article-title":"Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy","volume":"35","author":"Chernin","year":"2012","journal-title":"Clin. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s11255-017-1717-5","article-title":"Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease","volume":"49","author":"Georgianos","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.12788\/jhm.3655","article-title":"Risk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta-analysis","volume":"16","author":"Holleck","year":"2021","journal-title":"J. Hosp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Stavros, F., Yang, A., Leon, A., Nuttall, M., and Rasmussen, H.S. (2014). Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114686"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: The HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"ref_44","first-page":"54","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: The randomized, placebo-controlled HARMONIZE-Global study","volume":"7","author":"Zannad","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000504078","article-title":"Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE","volume":"50","author":"Roger","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/gfz285","article-title":"Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: Comparative results from an open-label, Phase 3 study","volume":"36","author":"Roger","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2019050450","article-title":"A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia","volume":"30","author":"Fishbane","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: Results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Imamura, T., Oshima, A., Narang, N., and Kinugawa, K. (2021). Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235523"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Murphy, D., Ster, I.C., Kaski, J.C., Anderson, L., and Banerjee, D. (2021). The LIFT trial: Study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02439-2"},{"key":"ref_51","unstructured":"(2022, June 02). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05004363."},{"key":"ref_52","unstructured":"(2022, June 02). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/205739Orig1s000TOC.cfm."},{"key":"ref_53","unstructured":"(2022, June 02). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/veltassa-epar-product-information_en.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ehf2.12292","article-title":"Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: Results from AMETHYST-DN","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ejhf.2386","article-title":"Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: Design and rationale of the DIAMOND trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.pcad.2020.09.007","article-title":"Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials","volume":"63","author":"Yuan","year":"2020","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zhuo, M., Kim, S.C., Patorno, E., and Paik, J.M. (J. Card. Fail., 2022). Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate vs. Patiromer, J. Card. Fail., Online ahead of print.","DOI":"10.1016\/j.cardfail.2022.04.003"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ekir.2018.10.020","article-title":"Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients","volume":"4","author":"Kovesdy","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/00325481.2019.1706920","article-title":"Real-world management of hyperkalemia with patiromer among United States Veterans","volume":"132","author":"Kovesdy","year":"2020","journal-title":"Postgrad. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10557-020-07134-2","article-title":"Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis","volume":"35","author":"Zhang","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_65","unstructured":"(2022, June 02). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lokelma-epar-product-information_en.pdf."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0897190017692921","article-title":"Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis","volume":"31","author":"Das","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/acem.13868","article-title":"Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study","volume":"27","author":"Rafique","year":"2020","journal-title":"Acad. Emerg. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e2145236","DOI":"10.1001\/jamanetworkopen.2021.45236","article-title":"Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting","volume":"5","author":"Sinnett","year":"2022","journal-title":"JAMA Netw. Open."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/00185787211037552","article-title":"Comparison of Patiromer to Sodium Polystyrene Sulfonate in Acute Hyperkalemia","volume":"57","author":"Nguyen","year":"2022","journal-title":"Hosp. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/acem.13954","article-title":"Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE)","volume":"27","author":"Peacock","year":"2020","journal-title":"Acad. Emerg. Med."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:11Z","timestamp":1760140331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,16]]},"references-count":70,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071721"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071721","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,16]]}}}